Synopsis: Gujarat Inject (Kerala) Limited reported strong FY26 growth, with Q4 revenue rising 1,783.44% QoQ to Rs. 30.70 crore and net profit increasing 4,000% QoQ to Rs. 1.64 crore.
This Micro-Cap Pharma Stock, engaged in manufacturing, trading, and marketing pharmaceutical products, healthcare formulations, and related medical products across domestic and international markets, is in focus after the company reported March quarterly results with a 1,783 percent revenue growth and 4,000 percent profit growth.
With a market capitalization of Rs. 148.03 crores, the shares of Gujarat Inject (Kerala) Limited hit a 2 percent lower circuit of Rs. 101.05 per share on Thursday, down from its previous closing price of Rs. 103.10 per share.
Q4 FY26 Result Walkthrough
Coming into the quarterly results of Gujarat Inject (Kerala) Limited, the company’s consolidated revenue from operations increased by 624.06 percent YOY, from Rs. 4.24 crore in Q4 FY25 to Rs. 30.70 crore in Q4 FY26, and grew by 1,783.44 percent QoQ from Rs. 1.63 crore in Q3 FY26.
In Q4 FY26, Gujarat Inject (Kerala) Limited’s consolidated net profit increased by 2,242.86 percent YOY, reaching Rs. 1.64 crore compared to Rs. 0.07 crore during the same period last year. As compared to Q3 FY26, the net profit has increased by 4,000 percent, from Rs. 0.04 crore. The basic earnings per share increased by 2,140 percent and stood at Rs. 1.12 as against Rs. 0.05 recorded in the same quarter in the previous year, FY2025.
Annual Performance of FY26
Gujarat Inject (Kerala) Limited’s revenue has increased from Rs. 19.05 crore in FY25 to Rs. 36.32 crore in FY26, which has grown by 90.66 percent. The net profit has also grown by 77.45 percent from Rs. 1.02 crore in FY25 to Rs. 1.81 crore in FY26. The annual basic earnings per share increased by 77.14 percent and stood at Rs. 1.24 as against Rs. 0.70 recorded in the financial year 2025.
Gujarat Inject (Kerala) Limited’s revenue and net profit have grown at a CAGR of 497.81 percent and 256.35 percent, respectively, over the last three years. In terms of return ratios, the company’s ROCE and ROE stand at 22.9 percent and 16.6 percent, respectively. Gujarat Inject (Kerala) Limited is a debt-free company.
Operations and Product Line
The company’s portfolio includes large-volume parenterals such as dextrose, saline, and ringer’s lactate solutions packaged in plastic bottles and bags. Its manufacturing adheres to Good Manufacturing Practice (GMP) standards, ensuring product sterility and compliance with national regulatory requirements. Gujarat Inject (Kerala) Limited supplies both public and private healthcare sectors.
Company Overview
Gujarat Inject (Kerala) Limited was incorporated in 1994 and is an Indian pharmaceutical and healthcare company engaged in manufacturing sterile medical products and infusion solutions. Based in Kerala, India, it specializes in producing intravenous fluids and related healthcare supplies for hospitals and clinical institutions across domestic and export markets.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
